Establishment of Animal Model of A Human Lung Adenocarcinoma Drug-resistant Cell Line Anip973/NVB and Investigation on Mechanism of Drug Resistance

Autor: Meng WANG, Xuan HONG, Qinwen SUN, Ruilin LI, Zhaoyang YANG, Gongyan CHEN

Publikováno v: Chinese Journal of Lung Cancer, Vol 15, Iss 3, Pp 146-151 (2012)

Background and objective Multidrug resistance (MDR) is the main cause of chemotherapeutic failure in lung cancer, and vinorelbine (NVB) is one of the most efficient drugs that threaten non-small cell lung cancer (NSCLC). The current study aims to est

Externí odkaz: https://doaj.org/article/9ffa705ce288457ba61e97aad401851f

Expression and significance of clusterin in Anip973/NVB cell lines

Autor: Wei LIU, Li CAI, Jinfeng NING, Dandan LI

Publikováno v: Chinese Journal of Lung Cancer, Vol 11, Iss 5, Pp 696-699 (2008)

Background and objective To detect clusterin expression in Anip973/Navelbine (Anip973/NVB) and wild type Anip973, the last one as a control, so as to conform that clusterin be association with the resistance to NVB of NSCLC. We detect the expression

Externí odkaz: https://doaj.org/article/4e9ef4aaa2ce4b10be7790e965b28ed5

Paclitaxel (Taxol)

Publikováno v: Top Drugs : Their History, Pharmacology, and Syntheses, 2015.

Externí odkaz: https://doi.org/10.1093/oso/9780199362585.003.0009

The NAME trial: a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer

Autor: T. Dongsgaard, Sven Tyge Langkjer, Lars Stenbygaard, Helle Lemvig Kruse, Julia Kenholm, Anne Sofie Brems-Eskildsen, Jeanette Dupont Jensen, Hella Danø, Bjørnar Gilje, Kim Wedervang, J. Neimann, Jürgen Geisler, Erik Hugger Jacobsen, Vesna Glavicic, Mie Grunnet, Annette Torbøl Brixen

Publikováno v: Langkjer, S T, Kenholm, J, Jensen, J D, Wedervang, K, Brixen, A T, Grunnet, M, Stenbygaard, L, Gilje, B, Danø, H, Glavicic, V, Jacobsen, E H, Brems-Eskildsen, A S, Kruse, H L, Dongsgaard, T, Neimann, J & Geisler, J 2019, ' The NAME trial : A direct comparison of classical oral Navelbine versus Metronomic Navelbine in metastatic breast cancer ', Future Oncology, vol. 15, no. 22, pp. 2561-2569 . https://doi.org/10.2217/fon-2019-0124
Langkjer, S T, Kenholm, J, Jensen, J D, Wedervang, K, Brixen, A T, Grunnet, M, Stenbygaard, L, Gilje, B, Danø, H, Glavicic, V, Jacobsen, E H, Brems-Eskildsen, A S, Kruse, H L, Dongsgaard, T, Neimann, J & Geisler, J 2019, ' The NAME trial : a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer ', Future Oncology, vol. 15, no. 22, pp. 2561-2569 . https://doi.org/10.2217/fon-2019-0124

Chemotherapy for metastatic breast cancer (MBC) is in general given in cycles of maximum tolerated doses to potentially maximize the therapeutic outcome. However, when compared with targeted therapies for MBC, conventional and dose intensified chemot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd3e68144dbea7113137cab419868c36
http://hdl.handle.net/10852/77735

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.